Introduction

Jenifer Chatting trusted a natural marijuana sleep aid to treat her insomnia, unaware the pills were quietly damaging her liver. Her story exposes critical gaps in Colorado's regulatory system that allowed hazardous products to remain on shelves for months without public warning.

What Happened

In 2022, Colorado health officials began receiving reports of acute liver injury linked to 1906 Midnight Drops, a marijuana-based sleep aid manufactured by Sima Sciences. Despite dozens of complaints and rising liver enzyme levels among users, the Marijuana Enforcement Division waited nearly 15 months before issuing any public warning. The product remained on dispensary shelves for months, even after the agency learned of the harm. Investigations revealed the manufacturer had reformulated the pills twice, swapping one liver-toxic herb for another with similar risks, while continuing to market the product as safe.

Why This Matters

The delay in warning consumers reveals deep structural flaws in Colorado's cannabis safety framework. Regulators rely on an honor-system testing model, allow manufacturers to retest products without strict timelines, and lack authority to enforce recalls except in rare health emergencies. Experts warn that seven-month average lag times between complaints and public notices leave products on shelves far too long, putting patients at risk. The case also exposes how industry influence and regulatory gaps can prioritize market stability over consumer protection.

Key Takeaways

  • Colorado regulators took an average of seven months to warn the public after receiving complaints about hazardous marijuana products.
  • The 1906 Midnight Drops product caused at least 52 reports of liver damage, 20 requiring medical care, before a second warning was issued in June 2023.
  • Manufacturers often continued selling products while challenging regulatory findings, exploiting loopholes in retesting rules.
  • State testing protocols lack independent sampling, relying instead on manufacturer-chosen labs and samples, which other states have moved away from.
  • The settlement between Sima Sciences and the Colorado attorney general's office resulted in a $400,000 fine and a ban on selling cannabis products in Colorado until 2027.

Conclusion

Jenifer Chatting’s liver damage could have been prevented if regulators had acted faster and communicated more clearly. Her experience serves as a cautionary tale about the risks of assuming natural cannabis products are automatically safe. As Colorado and other states continue refining their cannabis regulations, this case underscores the urgent need for faster warning systems, independent testing, and stronger consumer protections to prevent similar harm.